Stephen Grimes

This inventor holds 22 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 2 EPO patents, primarily in Immunotherapy Research. Top assignees: Aphton Corporation, Cancer Advances, Inc., Receptor Biologix, Inc.. Active years: 1989-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Grimes. Retrieved from https://idiyas.com/inventor/stephen-grimes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 1)

% Patents Active = 86.4

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 2

Average Co-Inventor Count = 2.7

ph-index = 11

Forward Citations = 298(Granted Patents)

Company Filing History:

Cancer Advances, Inc.

patents

1 out of 1

Receptor Biologix, Inc.

patent

Years Active: 1989-2014

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Gastrin Hormone

Immunogenic Compositions

Pancreatic Cancer

Tumor Treatment

Chimeric Peptides

Gastrointestinal Disorders

Hormone-Dependent Tumors

Immunization Methods

Peptide Immunogens

Cancer Immunotherapy

Gastrin Receptor

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8808695 - Monoclonal antibodies to progastrin (2014-08-19),

2. 8388966 - Combination treatment of pancreatic cancer (2013-03-05),

3. 8343930 - Combination therapy for the treatment of tumors (2013-01-01),

4. 8158128 - Monoclonal antibodies to progastrin (2012-04-17),

5. 7964371 - Gastrin hormone immunoassays (2011-06-21),

6. 7235376 - Gastrin hormone immunoassays (2007-06-26),

7. 6861510 - Immunogenic compositions against gastrin peptides (2005-03-01),

8. 6783761 - Chimeric peptide immunogens (2004-08-31),

9. 6548066 - Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors (2003-04-15),

10. 6359114 - System for method for the modification and purification of proteins (2002-03-19),

11. 6303123 - Methods for the treatment of hormone-dependent tumors with immunogens against gonadotropin releasing hormone (2001-10-16),

12. 6132720 - Immunogens against gonadotropin releasing hormone (2000-10-17),

13. 5866128 - Method for the treatment and prevention of gastric and duodenal ulcer (1999-02-02),

14. 5785970 - Method of the treatment of gastrointestinal disorders with immunogenic (1998-07-28),

15. 5688506 - Immunogens against gonadotropin releasing hormone (1997-11-18),

Title: Stephen Grimes: Innovator in Monoclonal Antibody Therapies

Introduction: Stephen Grimes is an accomplished inventor based in Davis, California, with an impressive portfolio of 22 patents to his name. His work primarily focuses on the development of therapeutic strategies to combat diseases related to gastrin, including pancreatic cancer. Grimes exemplifies the role of innovation in the field of biotechnology.

Latest Patents: Among his latest contributions, Grimes has developed monoclonal antibodies that specifically bind to progastrin. This invention aims to provide therapeutic options for passive immunization against progastrin in gastrin-promoted diseases or conditions. Notably, these progastrin-binding molecules do not interact with alternative forms of gastrin, including gastrin-17, gastrin-34, glycine-extended gastrin-17, or glycine-extended gastrin-34. His work also encompasses a combination treatment for pancreatic cancer, showcasing a commitment to addressing significant medical challenges through innovative research.

Career Highlights: Grimes has played a crucial role in various companies, including Aphton Corporation and Cancer Advances, Inc. His career has centered around utilizing his expertise in antibody development and oncology to drive forward impactful healthcare solutions.

Collaborations: Throughout his career, Grimes has collaborated with notable colleagues, such as Philip C. Gevas and Stephen L. Karr. These partnerships have enhanced his research capabilities and have been instrumental in advancing his innovations in antibody therapies.

Conclusion: Stephen Grimes continues to make significant strides in the field of biotechnology through his patented inventions and collaborations. His focus on monoclonal antibodies positions him as a leading inventor in the fight against gastrin-related diseases, including pancreatic cancer, thus contributing to the advancement of medical science and patient care.

Profile summary based on public USPTO records.